CRMD CorMedix Inc.

6.81
+0.15  (+2%)
Previous Close 6.66
Open 6.64
Price To Book 6.08
Market Cap 174,694,376
Shares 25,652,625
Volume 170,480
Short Ratio 14.08
Av. Daily Volume 266,740
Stock charts supplied by TradingView

NewsSee all news

  1. CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  2. CorMedix Inc. to Report Third Quarter 2019 Financial Results and Provide a Corporate Update on November 14

    BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  3. CorMedix Inc. Announces a Change to its Senior Leadership

    BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  4. CorMedix Inc. to Present at the Cantor 2019 Global Healthcare Conference

    BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  5. CorMedix Inc. Announces Exercises of Outstanding Warrants

    BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA to be filed 1H 2020.
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 to be initiated pending funding.
Neutrolin - LOCK-IT 200
Oncology patients on Total Parental Nutrition (TPN)

Latest News

  1. CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  2. CorMedix Inc. to Report Third Quarter 2019 Financial Results and Provide a Corporate Update on November 14

    BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  3. CorMedix Inc. Announces a Change to its Senior Leadership

    BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  4. CorMedix Inc. to Present at the Cantor 2019 Global Healthcare Conference

    BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  5. CorMedix Inc. Announces Exercises of Outstanding Warrants

    BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  6. CorMedix Inc. to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    BERKELEY HEIGHTS, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of